KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Assets: 2017-2024

Historic Assets for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $3.5 billion.

  • Amneal Pharmaceuticals' Assets rose 4.01% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 billion, marking a year-over-year increase of 4.01%. This contributed to the annual value of $3.5 billion for FY2024, which is 0.83% up from last year.
  • Amneal Pharmaceuticals' Assets amounted to $3.5 billion in FY2024, which was up 0.83% from $3.5 billion recorded in FY2023.
  • Amneal Pharmaceuticals' Assets' 5-year high stood at $4.0 billion during FY2020, with a 5-year trough of $3.5 billion in FY2023.
  • Moreover, its 3-year median value for Assets was $3.5 billion (2024), whereas its average is $3.6 billion.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Assets grew by 9.28% in 2020 and then declined by 8.60% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Assets stood at $4.0 billion in 2020, then fell by 1.66% to $3.9 billion in 2021, then fell by 3.56% to $3.8 billion in 2022, then decreased by 8.60% to $3.5 billion in 2023, then rose by 0.83% to $3.5 billion in 2024.